Medtronic has secured CE Mark approval for its TYRX absorbable antibacterial envelope, which covers an implantable cardiac device and reduces surgical-site infections.

The efficacy of the previous generation, non-absorbable TYRX Antibacterial Envelope has been shown in three published studies, with new six-month follow-up data from the CITADEL/CENTURION trial.

The company said that six months after implantation, patients who received a single or dual-chamber implantable cardioverter-defibrillator (ICD) or cardiac resynchronisation therapy (CRT) replacement device with a TYRX Antibacterial Envelope experienced lower infection rates compared with a group of patients implanted without the envelope.

According to the trial, infection occurred in 0.2% of patients who received the envelope during an ICD or CRT implant, compared with 1.9% of patients who did not receive the envelope.

"The TYRX envelope seems to offer physicians a simple, yet highly effective method of reducing surgical-site infections, particularly among those high-risk patients who are undergoing a repeat procedure."

In addition, the rate of device mechanical complications was low (4%) in patients who received the envelope.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

The multi-centre CITADEL/CENTURION trial included 55 sites in the US that prospectively treated over 1,000 patients undergoing an ICD or CRT replacement with the TYRX Antibacterial Envelope.

Primary endpoints of the trial were major infection (involving any site other than skin or subcutaneous tissue of the incision or endocarditis) and device mechanical complication.

Sahlgrenska University Hospital professor Charles Kennergren said: "The TYRX envelope seems to offer physicians a simple, yet highly effective method of reducing surgical-site infections, particularly among those high-risk patients who are undergoing a repeat procedure.

"We have high expectations for this novel product, both in terms of reducing infection rates as well as avoiding device migrations."

Currently approved for use in the US, Canada and Israel, the envelope has been designed to cover a cardiac implantable electronic device (CIED) such as pacemaker and ICD or CRT device.

It releases rifampin and minocycline at the surgical site, which helps in preventing infection.

Medtronic senior vice-president and cardiac rhythm and heart failure business president John Liddicoat said: "While the risk of infection is low for most patients receiving an implantable device, the TYRX envelope offers an extra layer of protection.

"The TYRX envelope provides physicians with a proven solution to make implantable device procedures safer for their patients."